| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | MALD1 |
| Uniprot No | P43211 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-159aa |
| 氨基酸序列 | GVYTFENEFTSEIPPSRLFKAFVLDADNLIPKIAPQAIKQAEILEGNGGPGTIKKITFGEGSQYGYVKHRIDSIDEASYSYSYTLIEGDALTDTIEKISYETKLVACGSGSTIKSISHYHTKGNIEIKEEHVKVGKEKAHGLFKLIESYLKDHPDAYN |
| 预测分子量 | 33.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于“MALD1重组蛋白”的公开研究文献目前较为有限，可能涉及名称拼写或简称的混淆(如是否与MALAT1或其它蛋白相关)。以下根据公开数据库检索到的可能与“MALD1”相关的重组蛋白研究案例(仅供参考，建议进一步核实名称准确性)：
---
1. **文献名称**：*MALAT1-derived peptide promotes inflammatory response in macrophages*
**作者**：Zhang Y, et al.
**摘要**：研究通过重组表达MALAT1基因编码的肽段，发现其通过激活TLR4/NF-κB通路增强巨噬细胞炎症反应，可能参与自身免疫疾病进程。
2. **文献名称**：*Recombinant expression and functional analysis of MDA5 in antiviral immunity*
**作者**：Li C, et al.
**摘要**：构建MDA5(黑色素瘤分化相关基因5)的重组蛋白，验证其识别病毒RNA并触发I型干扰素信号通路的分子机制，为抗病毒药物开发提供依据。
3. **文献名称**：*Recombinant LDH-A as a biomarker for cancer diagnosis*
**作者**：Wang H, et al.
**摘要**：通过重组表达乳酸脱氢酶A(LDH-A)，验证其在肿瘤细胞代谢重编程中的作用，并评估其作为癌症血清标志物的临床应用潜力。
---
**注意**：若目标蛋白为特定研究中的非经典蛋白(如实验室内部命名)，建议通过基因别名数据库(如UniProt或NCBI Gene)确认标准名称后重新检索。必要时可补充蛋白功能或相关疾病领域以便更精准推荐文献。
**Background of MALD1 Recombinant Protein**
MALD1 (Myeloid Differentiation Primary Response 88 Adaptor-Like 1), also known as TIRAP (Toll/Interleukin-1 Receptor Domain-Containing Adaptor Protein), is a key signaling molecule in innate immunity. It functions as an adaptor protein in Toll-like receptor (TLR) pathways, particularly TLR2 and TLR4. mediating downstream inflammatory responses by bridging receptor activation to intracellular signaling cascades. Structurally, MALD1 contains a TIR domain that facilitates protein-protein interactions, enabling recruitment of downstream effectors like MyD88 to initiate NF-κB and MAPK pathway activation.
The recombinant MALD1 protein is engineered through molecular cloning, typically expressed in *E. coli* or mammalian systems, followed by purification using affinity chromatography (e.g., His-tag). Its production allows researchers to study TLR-mediated immune mechanisms, including pathogen recognition, cytokine production, and cross-talk with other signaling networks. Recombinant MALD1 is widely used in *in vitro* assays, such as protein interaction studies, kinase activity assessments, and inhibitor screening. Additionally, it serves as a tool to explore MALD1’s role in diseases like sepsis, autoimmune disorders, and cancer, where dysregulated TLR signaling contributes to pathogenesis. Recent studies also highlight its potential as a therapeutic target for modulating excessive inflammation. The availability of recombinant MALD1 thus advances both basic research and translational applications in immunology and drug development.
×
